



05 January, 2016

3 - 2 - 4 , K o j i m a c h i , C h i y o d a , T o k y o
Company Name 3 - D M a t r i x , L t d .
P r e s i d e n t K e n t a r o T a k a m u r a
C o d e N u m b e r 7 7 7 7
C o n t a c t D i r e c t o r T o m o y u k i A r a i
T E L + 8 1 3 (3 5 1 1) 3 4 4 0

Patent granted on “3-D Cell Culture Scaffold” in Canada
with self-assembling peptide technology
exclusively licensed by MIT

In regards to a self-assembling peptide technology that the company has exclusive licensing rights from the Massachusetts Institute of Technology (hereafter, “MIT”), the company hereby announces that a patent filed by MIT, the licensor, related to bone / cartilage regeneration and skin regeneration fields in which developments are in progress was granted in Canada.

[Name of invention] Peptide scaffold encapsulation of tissue cells and uses thereof

[Patent number] No. 2344954

[Patent holder] Massachusetts Institute of Technology

This patent relates to three-dimensional scaffold comprised of self-assembling peptide, which encapsulates cells, chemoattractant and so on, and methods of forming it wherein said cells are such as chondrocytes, fibroblasts, neuronal cells, epidermal cells, endothelial cells, pancreatic cells, liver cells, bone marrow cells and embryonic stem cells. This patent also covers its application in tissue regeneration for treating or preventing a cartilage defect, epidermal lining defect, endothelial lining defect, arthritis, connective tissue defect (such as ligaments and tendons) and nervous tissue defect.

The company is working to achieve distribution partnership and licensing out in regards to wound healing material (TDM-511) which is an approved product in the US and dental bone void filler (TDM-711), a clinical trial of which is in progress in the US. This licensed patent from MIT for three-dimensional scaffold and its application in tissue regeneration was granted this time after US, EU and Japan and is expected to reinforce the license with its wide coverage of wide applicable cell types. The company’s patents on self-assembling peptide technology is also strengthened with the granted patent and is expected to contribute partnership agreement, license out and so on mainly for North America in the future.

It is also expected that this patent would protect rights of future pipeline candidates such as bone /

cartilage regeneration material the researches of which have been promoted at Center of Innovation (COI) project of University of Tokyo (joint research with such as Professor Tsuyoshi Takato, Graduate School of Medicine of University of Tokyo) toward clinical application.

The announcement is considered to contribute enhancing value of joint research and intellectual property in the next fiscal year or later, even though it does not influence the earning forecast of the company at this moment.